Polana Therapeuticssp. z o.o.
Research and experimental development in natural sciences and engineering
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2025-12-12
Share capital
5 000,00 PLN
Registered address
ul. Żwirki I Wigury 101, 02-089 Warszawa, Poland
Electronic delivery address
AE:PL-65273-15810-FETTU-24
Industry
Bank accounts
Registered as a VAT taxpayer on 2026-04-02. Active
80 1090 1056 0000 0001 6567 7127
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Barbara Dymek — Attorney-in-fact
Zbigniew Jan Zasłona — President of the Management Board
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Piotr Iwanowski (55) | Osoba jest prezesem zarządu spółki dominującej nad zgłaszaną spółką. |
Macin Szumowski (58) | Osoba jest prezesem zarządu spółki dominującej nad zgłaszaną spółką. |
Zbigniew Zasłona (45) | Osoba jest prezesem zarządu spółki dominującej nad zgłaszaną spółką. |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Smart FluidS.A. | $681,963.98 | smartfluid.pl | |
| Lymelab Pharma sp. z o.o.sp. k. | $424,756.39 | lymelabpharma.com | |
| Oasis DiagnosticsS.A. | $282,613.94 | oasis-diagnostics.com | |
| NanosanguisS.A. | $192,701.50 | nanosanguis.com | |
| NanovelosS.A. | $24,842.03 | nanovelos.com | |
| Nanostalsp. z o.o. | $8,607.48 | nanostal.com | |
| NanotheaS.A. | $115.78 | nanothea.com | |
| MolecureS.A. | $10.77 | molecure.com | |
| Syn2bioS.A. | — | syn2bio.pl | |
| Biorenomésp. z o.o. | — | biorenome.pl |
FAQ
The main business activity of Polana Therapeutics focuses on research and experimental development in natural sciences and engineering.
The company was registered in the Polish National Court Register (KRS) on December 12, 2025.
The headquarters is located at: ul. Żwirki I Wigury 101, 02-089 Warszawa.
The management board includes Zbigniew Jan Zasłona (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
Last updated: 2026-04-25
